Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Shares of The Medicines Company Sank 14.5% Today

By Brian Orelli, PhD - Dec 13, 2018 at 5:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors aren't happy about the drugmaker's latest capital raise.

What happened

Shares of The Medicines Company (MDCO) dropped 14.5% on Thursday following an announcement after the bell on Wednesday that the drugmaker plans to raise $150 million selling convertible notes, with the potential to raise another $22.5 million if the purchaser uses its overage option.

So what

Convertible notes, sometimes referred to as convertible bonds, are essentially a loan that can be repaid by the company using cash, shares, or a combination of the two. The chance of being repaid in cash makes them slightly better for investors than secondary offerings, where investors are diluted instantly, but the reality of the situation is many -- if not most -- drug companies issuing convertible notes end up repaying them with shares. And in the meantime, the company has to pay interest on the notes -- albeit at a lower interest rate than just issuing an unsecured bond.

The Medicines Company hasn't announced the interest and conversion rate for the notes yet, so it's hard to know how expensive the capital raise is going to be for current shareholders. Investors are clearly worried that the conversion rate will be low enough that the notes could end up creating substantial dilution if The Medicines Company can't repay the notes in cash.

Balance sheet with pen and magnifying glass

Image source: Getty Images.

Investors may also be getting nervous about the takeover of the company's board by activist investor Alex Denner, which resulted in the ousting of longtime CEO Clive Meanwell -- who moved into a newly created role of chief innovation officer this week.

Now what

The notes aren't due until 2024, so The Medicines Company has some time to get to cash-flow positive. In fact, its cholesterol-lowering drug inclisiran is wrapping up clinical development and should be submitted to U.S. and EU regulators in late 2019 and early 2020, respectively.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

The Medicines Company Stock Quote
The Medicines Company

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.